Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.
Meshaal AlanziMohammad Abu-TinehLajos SzabadosM Z Sharaf EldeanSali AlatasiRuba Y TahaSarah A ElkourashyPublished in: OncoTargets and therapy (2023)
Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.
Keyphrases
- diffuse large b cell lymphoma
- high intensity
- hodgkin lymphoma
- acute lymphoblastic leukemia
- acute myeloid leukemia
- stem cells
- resistance training
- squamous cell carcinoma
- rheumatoid arthritis
- case report
- machine learning
- combination therapy
- replacement therapy
- artificial intelligence
- bone marrow
- body composition
- rectal cancer